Evommune Q2 2026: $288M Cash, Phase 2b AD Data in September, Migraine Trial Underway
EVMN sits 25% above its 52-week low of $10.47.
Summary
Evommune's Q2 2026 update highlights a $288M cash runway through 2028, with the pivotal EVO756 Phase 2b atopic dermatitis data readout set for September 2026 — the key catalyst after the CSU trial failure.
Key Events · Earnings and Guidance · EVMN
-
Q2 2026 Financial Results
Cash, equivalents, and investments stood at $288.0 million as of June 30, 2026, up from $216.7 million at year-end 2025. With zero revenue, the net loss reached $32.2 million ($0.89/share), driven by R&D expense of $26.4 million.
-
Cash Runway Through 2028
Management confirms the balance sheet funds operations through 2028, covering multiple key data readouts including EVO756 in AD and migraine, and the initiation of the EVO301 Phase 2b.
-
EVO756 Phase 2b AD Data in September 2026
Top-line data from the fully-enrolled 120-patient dose-ranging trial in moderate-to-severe atopic dermatitis is expected next month. The primary endpoint is percent change in EASI at Week 12.
-
EVO756 Migraine Phase 2b Initiated
A 330-patient dose-ranging trial in refractory migraine prophylaxis began in July 2026, with top-line data anticipated in 2027. The primary endpoint is change in monthly migraine days.
Analysis · EVMN · Life Sciences
Evommune's Q2 2026 financials reveal a robust $288 million cash position that funds operations through 2028, eliminating near-term financing risk. The next major value driver is now confirmed: pivotal Phase 2b atopic dermatitis data for EVO756 will read out in September 2026. Despite the recent CSU failure, pipeline breadth is evident from the newly initiated Phase 2b migraine trial and positive Phase 2a data for EVO301. While R&D spending pushed the net loss to $32.2 million, the ample cash runway provides a comfortable cushion.
At the time of this filing, EVMN was trading at $13.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $481.9M. The 52-week trading range was $10.47 to $33.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.